Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies
Detection Principle
ImmunoAssay-Antibody
Target
IgM and IgG
Testing Method Category
Mixed
Testing Method
Maglumi2019-n-Cov IgG and IgM and Euroimmun Anti-SARS-CoV-2 IgG and IgA assays, 019-n-CoVIgG/IgMrapidtestcassette(LaboOnTime), 2019-n-CoV) antibody IgG/IgM assay(colloidal gold) (Avioq), QuickZen COVID-19 IgM/IgG Kit (QuickZen)
Testing Method - Additional Info
assesstheperformanceoffiveimmunoassaysforthedetectionofSARS-CoV-2antibodies.
Reported Performance
sensitivity at day 15: ELISA: IgA or IgG 93.93%, IgA 93.93%, IgG 90.9%;CLIA: IgM or IgG 93.75%, IgM 87.5%, IgG 87.5%; Lateral flow test: Avioq 93.93%, QuickZen 90.9%, LabOn Time 93.93%
Sample Size
200 samples
Peer-reviewed
yes
The database contains available information from scientific literature that is being updated periodically. Please note that the provided information (as retrieved from analysed papers) is provided only for devices commercially available with CE-IVD mark. Acknowledgements